Simultaneous Integrated Boost: Improving the Patient Journey During Breast Cancer Radiotherapy Safely

Sanjoy Chatterjee(Tata Medical Center), Santam Chakraborty(Tata Medical Center), S. Mandal(Bose Institute), A. Mahata(Tata Medical Center)

Clinical Oncology

December 29, 2018

10.1016/j.clon.2018.12.004

Cited by 11

Related Papers

Human papillomavirus in head and neck cancer in India: Current status and consensus recommendations

|South Asian Journal of Cancer|2017|48

HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis

|Radiotherapy and Oncology|2022|42

Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis

|Practical Radiation Oncology|2018|32

Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial

|Trials|2020|29

Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity

|European Journal of Cancer|2022|29